Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243552 | 0.97 | LMNA (0.40) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL553541 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL555010 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| Methylamine SCHEMBL17749558 | 0.91 | FDPS (0.41) | LMNAFDPSCA2ALDH1A1 | |
| Tetramethylammonium Ion SCHEMBL238777 | 0.88 | LMNA (0.35) | LMNAFDPSCA2 | |
| SCHEMBL571123 | 0.85 | LMNA (0.36) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL27947422 | 0.84 | PGK1 (0.35) | LMNAFDPS | |
| SCHEMBL3817093 | 0.82 | LMNA (0.41) | LMNAFDPSCA2ALDH1A1 | |
| SCHEMBL18394941 | 0.81 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL2871051 | 0.80 | FDPS (0.45) | LMNAFDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323491-A1 | CLEANING COMPOSITION | Entegris, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117295811-A | cleaning composition | 恩特格里斯公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-110740993-B | Deuterated pyridonamides and prodrugs thereof useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20220336210-A1 | CLEANING COMPOSITION | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2022-10-20 | — | — | US | disclosed |
| WO-2022221497-A1 | CLEANING COMPOSITION | ENTEGRIS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-108395452-B | Prodrugs of pyridone amides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-110740993-A | Deuterated pyridone amides and prodrugs thereof as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-01-31 | — | — | CN | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | LMNA 857/4885FDPS 1728/4885CA2 176/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | LMNA 4198/4885FDPS 115/4885CA2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.